Immunoprecise Antibodies Share Price (NASDAQ: IPA)

$3.21

▲

0.58

(22.05%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Immunoprecise Antibodies Stock chart to analyse performance

Immunoprecise Antibodies stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$2.67
Today's High:$3.21
$3.21
16.82%
Downside
Day's Volatility :16.82%
Upside
0.0%
52 Weeks Low:$0.27
52 Weeks High:$3.21
$3.21
91.59%
Downside
52 Weeks Volatility :91.59%
Upside
0.0%

Immunoprecise Antibodies Stock Returns

Period	Immunoprecise Antibodies Ltd	Index (Russel 2000)
3 Months	498.31%	0.0%
6 Months	686.36%	0.0%
1 Year	294.44%	0.0%
3 Years	-48.55%	-7.8%

Immunoprecise Antibodies Ltd Key Stats

Check Immunoprecise Antibodies key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$2.63
Open	$2.67
Today's High	$3.21
Today's Low	$2.67
Market Capitalization	$121.4M
Today's Volume	$3.0M
52 Week High	$3.21
52 Week Low	$0.27
Revenue TTM	$24.5M
EBITDA	$-9.3M
Earnings Per Share (EPS)	$-0.66
Profit Margin	-123.3%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-101.96%

Stock Returns calculator for Immunoprecise Antibodies Stock including INR - Dollar returns

The Immunoprecise Antibodies stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Immunoprecise Antibodies investment value today

Current value as on today

₹4,00,612

Returns

₹3,00,612

(+300.61%)

Returns from Immunoprecise Antibodies Stock

₹2,96,296 (+296.3%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Immunoprecise Antibodies Stock

-27%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Search interest for Immunoprecise Antibodies Stock from India on INDmoney has decreased by -27% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Immunoprecise Antibodies Ltd

Name
Holdings %
Name
Holdings %
Ingalls & Snyder LLC
6.02%
Susquehanna International Group, LLP
1.52%
Two Sigma Investments LLC
0.20%
Virtu Financial LLC
0.13%
CIBC World Markets Inc.
0.09%
Group One Trading, LP
0.07%

Analyst Recommendation on Immunoprecise Antibodies Stock

Rating

Trend

Buy

83%Buy

16%Hold

0%Sell

Based on 6 Wall street analysts offering stock ratings for Immunoprecise Antibodies(by analysts ranked 0 to 5 stars)

Immunoprecise Antibodies Share Price Target

What analysts predicted

Upside of 24.61%

Target:

$4.00

Current:

$3.21

Immunoprecise Antibodies share price target is $4.00, a slight Upside of 24.61% compared to current price of $3.21 as per analysts' prediction.

Immunoprecise Antibodies Stock Insights

Price Movement
In the last 7 days, IPA stock has moved up by 59.7%
Increasing Revenue
Revenue is up for the last 4 quarters, 5.26M → 6.98M (in $), with an average increase of 8.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -21.52M → -2.16M (in $), with an average increase of 895.9% per quarter
IPA vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 109.5% return, outperforming this stock by 159.5%

Immunoprecise Antibodies Ltd Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Revenue	$10.0M	↑ 28.67%
Net Income	$-3.5M	↓ 35.05%
Net Profit Margin	-35.19%	↑ 34.52%

	FY21	Y/Y Change
Revenue	$14.3M	↑ 27.41%
Net Income	$-5.9M	↑ 48.37%
Net Profit Margin	-40.98%	↓ 5.79%

	FY22	Y/Y Change
Revenue	$15.3M	↑ 8.11%
Net Income	$-13.2M	↑ 127.64%
Net Profit Margin	-86.29%	↓ 45.31%

	FY23	Y/Y Change
Revenue	$15.3M	↑ 6.72%
Net Income	$-19.7M	↑ 58.96%
Net Profit Margin	-128.53%	↓ 42.24%

	FY24	Y/Y Change
Revenue	$17.9M	↑ 18.65%
Net Income	$-19.9M	↑ 2.32%
Net Profit Margin	-110.85%	↑ 17.68%

	FY25	Y/Y Change
Revenue	$17.5M	↑ 0.01%
Net Income	$-21.6M	↑ 11.25%
Net Profit Margin	-123.3%	↓ 12.45%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$4.6M	↑ 1.15%
Net Income	$-2.0M	↑ 2.17%
Net Profit Margin	-43.06%	↓ 0.43%

	Q2 FY24	Q/Q Change
Revenue	$4.7M	↑ 3.83%
Net Income	$-13.2M	↑ 573.57%
Net Profit Margin	-279.38%	↓ 236.32%

	Q3 FY24	Q/Q Change
Revenue	$3.8M	↓ 18.52%
Net Income	$-2.9M	↓ 77.84%
Net Profit Margin	-75.98%	↑ 203.4%

	Q4 FY24	Q/Q Change
Revenue	$4.5M	↑ 16.38%
Net Income	$-1.9M	↓ 36.16%
Net Profit Margin	-41.68%	↑ 34.3%

	Q1 FY25	Q/Q Change
Revenue	$4.3M	↑ 0.42%
Net Income	$-15.0M	↑ 742.97%
Net Profit Margin	-349.88%	↓ 308.2%

	Q2 FY25	Q/Q Change
Revenue	$5.0M	↑ 13.49%
Net Income	$-1.5M	↓ 89.96%
Net Profit Margin	-30.96%	↑ 318.92%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Profit	$5.7M	↑ 51.73%

	FY21	Y/Y Change
Profit	$9.2M	↑ 43.61%

	FY22	Y/Y Change
Profit	$8.7M	↓ 4.81%

	FY23	Y/Y Change
Profit	$8.6M	↑ 5.28%

	FY24	Y/Y Change
Profit	$8.8M	↑ 4.24%

	FY25	Y/Y Change
Profit	$9.7M	↑ 12.4%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$2.4M	↑ 8.23%

	Q2 FY24	Q/Q Change
Profit	$2.3M	↓ 2.78%

	Q3 FY24	Q/Q Change
Profit	$1.7M	↓ 24.2%

	Q4 FY24	Q/Q Change
Profit	$2.5M	↑ 45.88%

	Q1 FY25	Q/Q Change
Profit	$2.3M	↓ 4.13%

	Q2 FY25	Q/Q Change
Profit	$3.2M	↑ 35.36%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Operating Cash Flow	$-990.1K	↓ 56.61%
Investing Cash Flow	$-1.1M	↓ 28.1%
Financing Cash Flow	$124.3K	↓ 98.13%

	FY21	Y/Y Change
Operating Cash Flow	$-480.0K	↓ 56.87%
Investing Cash Flow	$-2.0M	↑ 55.14%
Financing Cash Flow	$34.7M	↑ 24730.42%

	FY22	Y/Y Change
Operating Cash Flow	$-7.9M	↑ 1553.5%
Investing Cash Flow	$-4.1M	↑ 112.05%
Financing Cash Flow	$2.3M	↓ 93.35%

	FY23	Y/Y Change
Operating Cash Flow	$-14.7M	↑ 99.91%
Investing Cash Flow	$-1.5M	↓ 62.23%
Financing Cash Flow	$-460.7K	↓ 121.54%

	FY24	Y/Y Change
Operating Cash Flow	$-3.1M	↓ 78.59%
Investing Cash Flow	$-1.1M	↓ 20.54%
Financing Cash Flow	$746.5K	↓ 264.41%

	FY25	Y/Y Change
Operating Cash Flow	$-4.6M	↑ 50.97%
Investing Cash Flow	$-571.8K	↓ 48.88%
Financing Cash Flow	$10.7M	↑ 1358.67%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-496.5K	↑ 183.4%
Investing Cash Flow	$42.5K	-
Financing Cash Flow	$457.0K	↓ 297.74%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-1.9M	↑ 296.85%
Investing Cash Flow	$-812.3K	↓ 2049.12%
Financing Cash Flow	$821.1K	↑ 83.2%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-1.3M	↓ 30.99%
Investing Cash Flow	$-191.8K	↓ 76.33%
Financing Cash Flow	$2.0M	↑ 140.07%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-1.6M	↑ 22.97%
Investing Cash Flow	$-47.3K	↓ 75.29%
Financing Cash Flow	$1.5M	↓ 23.26%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-835.9K	↓ 46.37%
Investing Cash Flow	$-77.8K	↑ 72.31%
Financing Cash Flow	$7.3M	↑ 409.71%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-815.9K	↓ 5.24%
Investing Cash Flow	$-256.9K	↑ 220.54%
Financing Cash Flow	$-299.2K	↓ 103.96%

Immunoprecise Antibodies Technicals Summary

Sell

Neutral

Buy

Immunoprecise Antibodies is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Immunoprecise Antibodies Ltd Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Immunoprecise Antibodies Ltd	38.31%	686.36%	294.44%	-48.55%	-80.0%
Regeneron Pharmaceuticals, Inc.	4.38%	-17.37%	-50.85%	-2.23%	-0.91%
Beone Medicines Ltd	5.81%	21.35%	61.84%	78.01%	32.14%
Vertex Pharmaceuticals Incorporated	-16.34%	-17.97%	-17.9%	35.76%	47.74%
Alnylam Pharmaceuticals, Inc.	38.5%	82.49%	66.63%	105.56%	244.81%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Immunoprecise Antibodies Ltd	NA	NA	NA	0.0	-1.02	-0.15	NA	0.51
Regeneron Pharmaceuticals, Inc.	15.08	15.08	1.23	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.25	28.25	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Immunoprecise Antibodies Ltd	Buy	$121.4M	-80.0%	NA	-123.3%
Regeneron Pharmaceuticals, Inc.	Buy	$63.4B	-0.91%	15.08	31.37%
Beone Medicines Ltd	NA	$38.2B	32.14%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.9B	47.74%	28.25	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	244.81%	NA	-12.96%

About Immunoprecise Antibodies Ltd

ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in Austin, Texas.

Organization	Immunoprecise Antibodies
Employees	81
CEO	Dr. Jennifer Lynne Bath Ph.D.
Industry	Miscellaneous

Key Management of Immunoprecise Antibodies Ltd

Name	Title
Dr. Jennifer Lynne Bath Ph.D.	CEO, President & Non-Independent Director
Mr. Joseph Scheffler	Interim Chief Financial Officer
Ms. Kari Graber	Vice President of Commercial Services
Mr. Dirk Van Hyfte M.D., Ph.D.	Chief Technology Officer
Mr. Frederic Chabot	Head of Corporate Development
Ms. Ingrid Brands M.D., Ph.D.	Chief Innovation & Strategy Officer
Ms. Lori Anderson	Vice President of Brand Marketing and Creative

Important FAQs about investing in IPA Stock from India :

What is Immunoprecise Antibodies share price today?

Immunoprecise Antibodies share price today is $3.21 as on August 23, 2025 at 1:29 AM IST at the close of the market. Immunoprecise Antibodies share today touched a day high of $3.21 and a low of $2.67.

What is the 52 week high and 52 week low for Immunoprecise Antibodies share?

Immunoprecise Antibodies share touched a 52 week high of $3.21 and a 52 week low of $0.27. Immunoprecise Antibodies stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $3.21, lower by 0% versus the 52 week high.

How to invest in Immunoprecise Antibodies Stock (IPA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Immunoprecise Antibodies on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Immunoprecise Antibodies Shares that will get you 0.4673 shares as per Immunoprecise Antibodies share price of $3.21 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Immunoprecise Antibodies Stock (IPA) from India?

Indian investors can start investing in Immunoprecise Antibodies (IPA) shares with as little as ₹87.521 or $1 (as of August 23, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Immunoprecise Antibodies stock (as per the Rupee-Dollar exchange rate as on August 23, 2025). Based on Immunoprecise Antibodies share’s latest price of $3.21 as on August 23, 2025 at 1:29 AM IST, you will get 3.1153 shares of Immunoprecise Antibodies. Learn more about fractional shares .

What are the returns that Immunoprecise Antibodies has given to Indian investors in the last 5 years?

Immunoprecise Antibodies stock has given -80.0% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?